前列腺癌治疗中的relugolix:临床证据和实际考虑
Arthur Peyrottes1, Michael Baboudjian2, Eric Barret3
1Hôpital Saint-Louis, AP-HP, Paris, France.
The French journal of urology
|July 25, 2025
概括
瑞卢戈力克斯是一种口服的淋巴腺素释放激素对手,为前列腺癌 (PC) 患者提供快速抑制. 与注射疗法相比,它显示出有效性,更快的恢复,以及潜在的心血管益处.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 安卓素剥夺疗法 (ADT) 是前列腺癌 (PC) 的标准治疗方法.
- 瑞卢戈力克斯是一种口服的淋巴腺激素释放激素对手,用于抑制.
研究的目的:
- 评估relugolix在前列腺癌中用于雄激素缺乏治疗的疗效和安全性.
- 为了比较relugolix与leuprolide在激素抑制和心血管事件方面.
主要方法:
- 在PubMed中进行了文献搜索,使用与relugolix和前列腺癌相关的术语.
- 包括以英语出版的前性和后性研究.
主要成果:
- 在HERO试验中,在接受relugolix的96.7%的患者中,持续性丸激素抑制被发现,而在接受leuprolide的患者中,这一比例为88.8%.
- 瑞卢戈利克斯证明了更快的抑制/恢复,并降低了54%的主要心血管不良事件的风险.
- 现实世界的研究证实了高效率 (>98%割水平) 和良好的坚持与relugolix.
结论:
- 瑞卢戈力克斯是前列腺癌的有效和方便的口服ADT选择,提供快速抑制和潜在的心血管益处.
- 需要进一步调查长期坚持,组合治疗和药物相互作用.
关键词:
在 GnRH 的对手.前列腺癌的前列腺癌.纳多释放激素的对抗者这是一种口服药物.前列腺新生体前列腺瘤.在Relugolix中使用.在血液中恢复丸激素.丸激素的恢复可以恢复.治疗口服治疗口服治疗更多相关视频
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.3K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.7K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K